Trials
4 active
5 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- Blocks endothelin, a signal that tightly narrows blood vessels.Endothelin Receptor Antagonist FDA class
- How it’s given
- “* 104 Weeks - Film-coated tablet * Other Names: Atrasentan Hydrochloride ABT-627”In the company’s words, NCT07498335 on ClinicalTrials.gov
- Tested for
- IgA Nephropathy (3 trials), Immunoglobulin A Nephropathy (3 trials), IgA Nephropathy (IgAN), Berger Disease, Bergers Disease, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type, Focal Segmental Glomerulosclerosis and 3 more
- Main trialPhase 3
- “The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.”In the company’s words, NCT04573478 on ClinicalTrials.gov
- Other names
- CHK01 · EXV811 · CHK-01 · ABT-627
Other drugs for IgA Nephropathy
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up3
- 14 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- 17 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Sep 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 14 Apr 2028 | Atrasentan in Patients With IgA Nephropathy | |
| Phase 3Not yet recruiting | 17 Sep 2028 | A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy | |
| Phase 3Recruiting | 15 Sep 2031 | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN | |
| Phase 2Active, not recruiting | 2 Jul 2024 | Atrasentan in Patients With Proteinuric Glomerular Diseases | |
| Phase 2Completed | 30 Jun 2025 | Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026